Visfatin

NAMPTprotein

Visfatin amplifies plaque inflammation and matrix degradation, destabilizing atherosclerotic lesions and increasing rupture and thrombotic risk.

Pathway placement

Cascade stepPlaque inflammation

Confidencehigh

RationaleProinflammatory adipocytokine; promotes vascular inflammation, atherosclerosis and plaque destabilization; AMI risk factor.

Also acts inMyocardial injury, Lipid entry/oxidation, Cap degradation / rupture

Druggability

DruggableYes

Known drugs / candidates3

Small-molecule tractableYes

Antibody tractableYes

EnsemblENSG00000105835

Type I vs Type II discrimination

ScoresLow-confidence (proxy)

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-31.5

Confounder panel (Type-II drivers)

No confounder evidence retrieved.

Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum or plasma

Collection tube

Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)

Method / principle

Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists

Reagent / substrate

Matched anti-target antibody pair (capture + labeled detection)

Platform

ELISA microplate or multiplex (Luminex/MSD)

Turnaround · availability

Send-out / research · Research-grade (no universal clinical assay)

0.017

Open Targets association (STEMI)